Efficacy of adjuvant chemotherapy schedules for breast cancer according to body mass index: results from the phase III GIM2 trial.
F PoggioE BlondeauxM TagliamentoM PerachinoS NardinB ConteM GiulianoG ArpinoM De LaurentiisA GravinaG BisagniA RimantiA TurlettiC NisticòE MagnolfiS GasparroA FabiO GarroneM G AliciccoY UrracciP PolettiP CorrealeC MolinelliA FozzaF PuglisiG ColantuoniP FregattiL BoniM LambertiniL Del MastroPublished in: ESMO open (2024)
In node-positive BC patients, DD schedule should be considered the preferred schedule irrespective of BMI.
Keyphrases
- phase iii
- body mass index
- open label
- clinical trial
- end stage renal disease
- phase ii
- ejection fraction
- newly diagnosed
- chronic kidney disease
- double blind
- peritoneal dialysis
- prognostic factors
- study protocol
- randomized controlled trial
- lymph node
- physical activity
- placebo controlled
- young adults
- patient reported outcomes